[4,6-dichloro-3-fluoro-5-(4'-hydroxy-3'-iso-propylphenoxy)-pyrid-2-ylamino]methylphosphonic acid | 627082-36-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [4,6-dichloro-3-fluoro-5-(4'-hydroxy-3'-iso-propylphenoxy)-pyrid-2-ylamino]methylphosphonic acid
• 英文别名: [[3,5-Dichloro-6-fluoro-4-(4-hydroxy-3-propan-2-ylphenoxy)pyridin-2-yl]amino]methylphosphonic acid
• CAS: 627082-36-4
• 化学式: C₁₅H₁₆Cl₂FN₂O₅P
• 分子量: 425.181
• InChiKey: ZHUBPAYEDHUCGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  112
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  L-丙氨酸乙酯 、 [4,6-dichloro-3-fluoro-5-(4'-hydroxy-3'-iso-propylphenoxy)-pyrid-2-ylamino]methylphosphonic acid 在 吡啶 、 2,2'-二硫二吡啶 、 三乙胺 、 三苯基膦 作用下， 反应 16.0h， 以25%的产率得到di-N-(L-1-ethoxycarbonylethylamino)[4,6-dichloro-3-fluoro-5-(4'-hydroxy-3'-iso-propylphenoxy)-pyrid-2-ylamino]methylphosphonamide
  参考文献：
  名称：

  Novel Phosphinic Acid-Containing Thyromimetics

  摘要：

  本发明涉及含有磷酸基T3拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟

  公开号：

  US20090028925A1

文献信息

• Novel Phosphorus-Containing Thyromimetics
  申请人：Erion Mark D.

  公开号：US20090118236A1

  公开（公告）日：2009-05-07

  The present invention relates to compounds of phosphonic acid containing T3 mimetics, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndromex and diabetes.

  本发明涉及含有T3类似物的膦酸化合物、立体异构体、药学上可接受的盐、共晶体和其前药物，以及前药物的药学上可接受的盐和共晶体，以及它们的制备和用于预防和/或治疗代谢性疾病，如肥胖症、NASH、高胆固醇血症和高脂血症，以及相关疾病，如动脉粥样硬化、冠心病、糖耐量受损、代谢综合征和糖尿病的用途。
• Novel phosphorus-containing thyromimetics
  申请人：Metabasis Therapeutics, Inc.

  公开号：EP2428516A1

  公开（公告）日：2012-03-14

  The present invention relates to compounds of phosphonic acid containing T3 mimetics, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome X and diabetes.

  本发明涉及含有T3模拟物的膦酸化合物、立体异构体、药学上可接受的盐、共晶体及其原药和原药的药学上可接受的盐和共晶体，以及它们在预防和/或治疗代谢性疾病（如肥胖、NASH、高胆固醇血症和高脂血症）以及相关疾病（如动脉粥样硬化、冠心病、糖耐量受损、代谢综合征X和糖尿病）方面的制备和用途。
• Novel Phosphinic Acid-Containing Thyromimetics
  申请人：Erion Mark D.

  公开号：US20090028925A1

  公开（公告）日：2009-01-29

  The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

  本发明涉及含有磷酸基T3拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟